Curanex Pharmaceuticals Inc (CURX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US23126K1060
Curanex Pharmaceuticals Inc financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -4.24 m USD |
| EBIT | -4.22 m USD |
| Net income | -4.23 m USD |
| Diluted EPS – continuing operations | -0.17 USD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.
More stocks
- GT Biopharma, Inc. (GTBP)
- Tempest Therapeutics, Inc. (TPST)
- Bodhi Tree Biotechnology Inc (BDTB)
- CFN Enterprises Inc. (CNFN)
- XERIANT, INC. (XERI)
- Bridgeline Digital, Inc. (BLIN)
- BTC Digital Ltd. (BTCT)
- Vynleads, Inc. (VYND)
- BARFRESH FOOD GROUP INC. (BRFH)
- SOLIGENIX, INC. (SNGX)
- Next Meats Holdings, Inc. (NXMH)
- KBS Real Estate Investment Trust III, Inc. (KBSR)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.